Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Kowa Pharmaceuticals America, Inc.Kowa Pharmaceuticals America Announces FDA Acceptance of New Drug Application for K-911, an Investigational IOP-Lowering Eye Drop for Patients with Open-Angle Glaucoma or Ocular HypertensionInvestigational K-911 is a once-daily nitric oxide-donating bimatoprost eye drop designed to lower intraocular pressure NDA is supported by two pivotal Phase 3 trials FDA assigns PDUFA target action date of April 30, 2027 MONTGOMERY, Ala., Aug. 27, 2026 -- Kowa...
- Susan G. Komen®Breast Cancer Continues to Impact Communities; Milwaukee Rallies Together to Take Action at Susan G. Komen® MORE THAN PINK WalkWISCONSIN, August 27, 2026--Susan G. Komen®, the world's leading breast cancer organization, today announced it will host the Wisconsin MORE THAN PINK Walk bringing together survivors, those living with metastatic breast cancer, families and supporters for a day of purpose and action. The event, taking place on Sunday, September 27, 2026, will raise critical funds to accelerate lifesaving research, expand patient support services, support critical public policy efforts and help ensure every pers
- Suffolk and CO Architects Selected to Deliver University of California, San Francisco Mission Bay Education Center and Dental Clinics ProjectSAN FRANCISCO, August 27, 2026--Suffolk, one of the most innovative and successful builders in the country, and CO Architects, a nationally recognized leader in health sciences and higher education design, have been selected to deliver the University of California, San Francisco (UCSF) Mission Bay Education Center and Dental Clinics project through a progressive design-build delivery model.
- Overseas Growth Gathers Momentum as CanSinoBIO's Global Strategy Unlocks New OpportunitiesCanSino Biologics Inc. (“CanSinoBIO,” 06185.HK/688185.SH) released its financial results for the first half of 2026. The Company reported revenue of approximately RMB 550 million, up 43.8% year on year, while its net loss attributable to shareholders narrowed significantly. Notably, while demand in China’s vaccine market remains challenging, CanSinoBIO’s international business maintained strong growth momentum, generating overseas revenue of RMB 150 million during the reporting period. As established products accelerate their expansion into overseas markets, and collaboration models such as technology partnerships and localized industrialization continue to take shape, CanSinoBIO’s overseas business is evolving from a strategic initiative into an increasingly important contributor to the Company’s performance. This reflects the Company’s forward-looking understanding of global vaccine market trends and evolving demand in international markets. At a time when the vaccine industry is facing changes in demand structure, the combination of domestic innovation capabilities and access to international markets is becoming an increasingly important measure of corporate growth resilience. Overseas Growth Accelerates In the first half of 2026, China’s vaccine industry continued to face demand-side pressure. As the target population for infant and young-child vaccination continues to decline, demand pressure on traditional pediatric vaccines has become increasingly visible. “Volume contraction and price decline” has emerged as a widespread challenge across the industry. Based on disclosed financial results across the sector, this pressure appears to be industry-wide. In 2025, Zhifei Biological generated RMB1.187 billion in revenue from self-developed products, up 1.23% year on year. Walvax Biotechnology reported 2025 revenue of RMB2.418 billion, down 14.29% year on year; despite a 53.36% year-on-year increase in batch-release volume for its core 13-valent pneumococcal conjugate vaccine, revenue remained under pressure. Kangtai Biological reported revenue of RMB1.273 billion in the first half of 2026, down 8.55% year on year. Against this industry backdrop, the growth of CanSinoBIO’s international business is particularly noteworthy. The Company reported overseas revenue of RMB 150 million in the first half of 2026. This growth was driven, on the one hand, by the continued expansion of mature products into overseas markets and, on the other, by the further deepening of the Company’s international partnership models. For CanSinoBIO, this also means that its products, manufacturing processes and quality control capabilities, validated in the domestic market, are beginning to unlock value overseas through more diversified approaches. Meanwhile, the Company continues to advance its international market footprint. Registration filings and commercialization efforts remain underway across Southeast Asia, South America and the Middle East. Menhycia(R) has obtained registration approvals in Indonesia and Argentina, and product supply has already commenced in Indonesia. As more products progress through overseas registration and commercialization, CanSinoBIO’s international business is expected to develop more diversified revenue streams and further strengthen its commercial resilience. From this perspective, CanSinoBIO’s globalization strategy is evolving. Overseas markets are no longer merely destinations for mature products, but are increasingly becoming markets in which products, technologies and industrial capabilities can jointly create value. For an innovative vaccine company, this shift from “exporting products” to “exporting capabilities and systems” creates greater room for long-term growth in its overseas business. Portfolio Upgrades Strengthen the Commercial Foundation Sustained overseas expansion is underpinned by a stable product portfolio and strong technological capabilities. According to the Company’s interim report, domestic revenue continued to grow despite factors such as changes in value-added tax, reflecting opportunities created by ongoing innovation. Menhycia(R), China’s first quadrivalent meningococcal conjugate vaccine, expanded its indicated population in February to children aged 3 months to 6 years, broadening its addressable population. Meanwhile, iPneucia(R), a 13-valent pneumococcal conjugate vaccine featuring dual-carrier technology (CRM197/TT), offers a differentiated option for pediatric pneumococcal disease prevention in China. Since its launch in September 2025, iPneucia(R) has continued to expand market access and is now available in nearly 30 provincial-level markets across China. From meningococcal disease to pneumococcal disease, CanSinoBIO is using innovative products to address vaccine segments that continue to offer meaningful unmet demand. As traditional vaccine categories face pressure on volumes, structural growth driven by product and technology upgrades is providing important support for the Company’s commercial resilience. More importantly, the product-development and industrialization capabilities established in the domestic market also provide a foundation for overseas expansion. For an innovative vaccine company, successful commercialization in China not only broadens revenue sources, but also validates the manufacturing, quality-control and supply systems required to replicate and extend those capabilities into international markets. Domestic product upgrades and overseas business growth are thereforeclosely connected rather than separate. The former provides the foundation in products and technologies, while the latter expands the geographic boundaries within which those products can realize their value. Multi-Layered Pipeline Takes Shape to Support Future Growth For an innovative vaccine company, long-term growth depends not only on the commercial performance of existing products, but also on the ability to maintain a steady flow of new products. By pursuing continued ramp-up of marketed products, advancing products under regulatory review and developing next-generation candidates, CanSinoBIO is building a more sustainable and well-sequenced product pipeline. Tripecia(R) (DT3cP Infant), CanSinoBIO’s three-component acellular diphtheria, tetanus and pertussis combined vaccine for infants, received NDA approval in April 2026, becoming the first approved three-component DTP vaccine in China. In August 2026, the first commercial batches received the Certificate for Batch Release of Biological Products. Provincial tendering and market-access processes are progressing in an orderly manner, and the product has begun entering the market supply stage. While Tripecia(R) represents an upgrade in pertussis vaccination for infants, the Td5cp vaccine for adolescents and adults — which has also been granted Priority Review status — is expected to extend CanSinoBIO’s pertussis vaccine portfolio to a broader population. The New Drug Application for Td5cp has been accepted by China’s National Medical Products Administration (NMPA). In addition, CanSinoBIO’s independently developed Adsorbed Tetanus Vaccine, Tetcia(R), has been formally approved, further strengthening the Company’s adult vaccine portfolio. From infants to adolescents and adults, and from individual products to a multi-product portfolio, this strategy is broadening the foundation for future commercial growth. In pneumococcal vaccines, CanSinoBIO’s 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (PCV24) formally initiated Phase I/II clinical trials in May 2026, and participant enrollment across different cohorts is progressing as planned. At the same time, the Company continues to advance development of its DT3cP-Hib-MCV4 combination vaccine, extending its portfolio toward increasingly multivalent and combination vaccine formats. Over the longer term, CanSinoBIO is continuing to build its mRNA platform and explore applications in preventive vaccines and therapeutic biologics. The Company is conducting early-stage research into mRNA applications for glioblastoma, rhabdomyosarcoma and cervical cancer, while also exploring in vivo CAR therapies. These programs remain at an early stage, with the Company continuing to assess the potential of mRNA and related technologies in disease treatment. Additionally, on August 25, CanSinoBIO announced that its subsidiary, CanSino Shanghai, had entered a strategic collaboration with deepGeneAI on mRNA therapeutic cancer vaccines. The two parties will leverage their respective strengths in mRNA vaccine technology and tumor neoantigen discovery and design to jointly advance the development and commercialization of personalized mRNA therapeutic cancer vaccines. These pipeline programs represent extensions of CanSinoBIO’s existing technology platforms and product-development experience. The Company’s core platforms — including viral vector vaccines, synthetic vaccines, protein structure design and VLP assembly, mRNA vaccines, as well as formulation and delivery technologies — provide a foundation for continued product iteration and technology translation. Innovation Supports Long-Term Development Viewed in the context of its 2026 interim results, CanSinoBIO’s story is not simply one of revenue growth. Against a changing domestic vaccine demand structure, innovative products have continued to deliver solid commercial performance, demonstrating the resilience created by product upgrades. Overseas business model expanded beyond finished-product exports to include technology collaboration and local manufacturing capabilities, indicating that international markets are becoming a new source of growth. At the same time, Tripecia(R) has entered the market supply stage, the Td5cp vaccine for adolescents and adults is progressing through regulatory review, and pipeline programs including PCV24, multivalent and combination vaccines, and mRNA technologies continue to advance, providing both product succession and technology reserves for the future. These three pathways ultimately point to the same growth logic: domestic innovation capabilities form the product foundation, overseas expansion broadens the commercial opportunity, and sustained R&D determines whether growth can continue over the long term. In an environment where demand for traditional vaccines is under pressure and industry competition is intensifying, growth is increasingly shifting away from reliance on product-volume expansion alone and toward a model jointly driven by product upgrades, technological innovation and global markets. For CanSinoBIO, continued growth in the overseas business is providing increasingly visible financial evidence of this transition. As more innovative products enter the market, more mature products expand overseas and the Company’s technical capabilities extend further into international value chains, CanSinoBIO’s growth runway is expanding from a single domestic market to the global market. For the Company, internationalization is not only about broadening geographic reach; it is also an important pathway for innovative products and technologies to realize greater commercial value while contributing to global public health.
- VVater LLCVVater Expands Global Presence Through New Partnership in Asia-Pacific and the Middle EastAUSTIN, TX, Aug 27, 2026 - VVater, America's Next Water Company and the world's premier innovator in advanced water treatment solutions, today announced an expanded international presence across Asia-Pacific Middle East (APME) as the company continues to scale its innovative water treatment technology globally and support new sectors. Via a new partnership agreement, VVater APME will be established. This newly formed venture will bring VVater's technology to a wide range of markets and strategic customers around the world as water scarcity, water quality, regulatory expectations and long-term water stewardship become increasingly important drivers of operational resilience and economic performance. VVater APME is a partnership formed between VVater and Ecosafe International, a regionally recognised water risk management and water stewardship consultancy, which supports organisations to navigate their water journey through governance, assurance, risk reduction and practical innovation. With an extensive track record supporting organisations including BHP, Rio Tinto, Chevron, Shell, JLL and NEOM, Ecosafe advises governments, mining operators, healthcare and industrial organisations on achieving safer, more sustainable and more resilient water outcomes across APME. VVater APME will operate with dedicated sector exclusivity in Australia, New Zealand, Saudi Arabia, Qatar and the UAE. "What drew us to this partnership is how much overlap there already was," said Kevin Gast, CEO and Chairman of VVater. "Ecosafe has spent years building trust with operators in some of the toughest water environments in the world. Pairing that with our technology means we can move faster into markets that badly need it." "For years we've watched clients wrestle with sourcing credible, provable water treatment technology once a risk assessment tells them what they're up against," said Ryan Milne, Founder of Ecosafe International. "This partnership closes a critical gap for us. We've always helped clients understand and govern water risk. Now we can combine that trusted advisory capability with proven technology solutions that accelerate the transition from water risk to water certainty." VVater APME is designed with a defined path to expand into installation, operations, and eventually in-territory manufacturing, creating long-term capability and supporting regional water security outcomes as the partnership matures. The agreement gives VVater APME access to VVater's full suite of proprietary technology, led by the Farady Reactor, a breakthrough in water treatment. Wherever it's deployed, from remote, self-managed water systems and mine sites to municipal water systems and industrial plants, the Farady Reactor transforms wastewater, sewage and drinking water alike, offering a glimpse of what next-generation water infrastructure can look like. VVater APME is the latest step in the company's international growth, following recognition from TIME, CES and Fast Company, and deployments with partners including Nestle and the City of Bastrop, Texas. The agreement reflects VVater's continued push to bring advanced treatment and reuse technology into markets facing mounting water stress. About VVater VVater is America's Next Water Company, delivering the future of purification through its award-winning Farady Reactor (Time Best Invention Award 2025, CES Best of Innovation 2025, World Future Award 2025. The first company in history to win all 3 in 1 year achieving a Triple Crown), proprietary ALTEP (Advanced Low Tension Electroporation Process), Advanced Dissolved Air Flotation, and Micro & Nano Bubble technologies. Unlike outdated chemical, filtration, and membrane systems, VVater's electric-field breakthroughs eliminate microplastics, microorganisms, and other contaminants with record retention times, without producing toxic byproducts or requiring costly consumables. With over 4.3B gallons treated and validation from global leaders, VVater is scaling into municipal drinking water and wastewater, DPR/IPR, onsite reuse for data centers, commercial buildings, and resorts, residential purification, and consumer health water, delivering a 60% smaller footprint, 40% CapEx savings, 80% OpEx savings, and 40% less energy use. For more information, please visit www.vvater.com. Contact Information VVATER Media Office Global Media Room [email protected] Nicholas Koulermos [email protected] SOURCE: VVater LLC
- Carrberry CompaniesCOMMHIT RECEIVES $43.6 MILLION DOLLAR GRANT: LAUNCHES VISION TO TRANSFORM RURAL HEALTHCARE ACROSS FLORIDAFrom lifesaving drones and AI-powered clinical support to Michael Feinstein's Music Forms Memories and hospital-level care at home, Dr. Kendra Siler is bringing together technology and humanity to create a powerful model for rural healthcare. KENNEDY SPACE CENTER, Fla., Aug. 27, 2026...
- Psilera, Inc.Psilera Appoints Neuroscience Veteran Allyson Gage, PhD, as Vice President, Clinical Development to Lead Upcoming Phase 1 Clinical TrialKey appointment strengthens operational leadership as Psilera prepares its lead neuroplastogen, PSIL-006, for clinical-stage evaluation. — Psilera Inc. ("Psilera"), a leading biopharmaceutical company pioneering next-generation neuroplastogens and...
- Jetstream Venture FundJetstream Venture Fund Expands Healthtech Portfolio with Investments in ImageAiD and Moonrise MedicalJetstream Venture Fund (Jetstream) announced its latest portfolio investments in healthtech pioneers ImageAiD and Moonrise Medical. Both companies are developing next-generation, AI-enabled vascular diagnostic platforms to transform the...
- NextGen® Behavioral Health Suite Ranked #1 Platform for Independent Behavioral Health Practices by Black Book Market ResearchREMOTE-FIRST COMPANY/TAMPA, Fla., August 27, 2026--NextGen Healthcare’s Behavioral Health Suite has been named the No. 1 platform for independent behavioral health practices in the Black Book Market Research Q3 2026 Behavioral Health EHR and Practice Management Platform Rankings for Independent Ambulatory Practices. This ranking is based on feedback from over 660 verified users representing 101 independent behavioral health organizations.
- Conavi Medical Reports Fiscal Third Quarter 2026 Results and Operational HighlightsConavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today reported financial results and provided an operational update for the fiscal quarter ended June 30, 2026 (“Fiscal Q3 2026”).
- Bausch Health Companies Inc.Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship WinnersThis year's Aspire Higher scholarships are awarded to six students who have been affected by dermatologic conditions. — Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its dermatology business,...
- XiFin, Inc.XiFin Research Quantifies Millions in Recoverable Revenue Across Ancillary Healthcare Revenue CyclesSAN DIEGO, August 27, 2026--XiFin, Inc., a leader in AI-driven revenue cycle management (RCM), today released new research conducted with Sage Growth Partners showing that growing reimbursement complexity, administrative burden, regulatory requirements, and patient financial responsibility are creating significant unrealized revenue cycle opportunity across complex healthcare service lines. Radiology practices, clinical laboratories, pathology groups, specialty pharmacies, and durable medical eq